• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Best and Worst US Cities for Patients with Seasonal Allergies

Article

With allergy season already here, the Asthma and Allergy Foundation of America (AAFA) recently released its annual Allergy Capitals™ report for 2021. The report identifies the most challenging cities for seasonal allergic rhinitis (ie, hay fever) in the top 100 US metropolitan areas. Cities are graded on 3 factors: Spring and fall pollen scores, over-the-counter medicine use, and availability of board-certified allergists. For each factor, the AAFA used the most recently available 12-month data.

In the slides below, find out which areas ranked most and least challenging for patients with seasonal allergies.

Related Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
ARS Pharma Submits Response to FDA Complete Response Letter for neffy (epinephrine nasal spray) / image credit word map anaphylaxis ©kalpis/stock.adobe.com

ARS Pharma Submits Response to FDA Complete Response Letter for neffy (epinephrine nasal spray)

April 3rd 2024
Article

Positive findings from a repeat dosing study of neffy under nasal allergen challenge conditions will support a potential PDUFA date of October 2, 2024, the company said.

Clinical Focus Business Focus Spotlight TGIF for Optinose Xhance: PDUFA Date Set for Saturday, March 16, 2024 / image credit nasal passages: ©turhanerbas/stock.adobe.com

Optinose Xhance approved by FDA as first medical therapy for CRS

March 15th 2024
Article

Now FDA approved, Optinose’s Xhance is the first nonsurgical option for chronic rhinosinusitis both with and without nasal polyps.

Neffy May be Safe, Effective for Treatment of Urticaria Flares: Daily Dose / image credit: ©New Africa/AdobeStock

Neffy May be Safe, Effective for Treatment of Urticaria Flares: Daily Dose

March 7th 2024
Article

Your daily dose of the clinical news you may have missed.

Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers / image credit: epipen injection: ©Rob Byron/stock.adobe.com

Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers

February 27th 2024
Article

AAAAI 2024. Needle phobia is just one of the barriers to not just using an epinephrine autoinjector but to carrying one at all, according to 2 sets of surveys findings.

New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares / Image credit: ©chomplearn 2001/AdobeStock

New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares

February 26th 2024
Article

AAAAI 2024. In patients with treatment-resistant chronic spontaneous urticaria, neffy 1 mg and 2 mg resulted in improvement in itch, hives, urticaria, and erythema scores 5 minutes after dosing.

Neffy Generates Favorable PK/PD Data Under Nasal Allergen Challenge in Repeat Dosing Study Requested by FDA / image credit pollen, allergy: ©jovan vitanovski/shutterstock.com

Neffy Generates Favorable PK/PD Data Under Nasal Allergen Challenge in Repeat Dosing Study Requested by FDA

February 26th 2024
Article

neffy (epinephrine nasal spray) delivered a PK and PD profile greater than or similar to that of IM epinephrine after extreme nasal challenge, reports ARS Pharmaceuticals.

© 2024 MJH Life Sciences

All rights reserved.